{
  "Variants Include": [
    {
      "Gene": "SNCA",
      "variants": [
        {
          "HGVS": "NM_000305.1:c.138G>A",
          "cDNA Change": {
            "transcript": "NM_000305.1",
            "ref": "G",
            "alt": "A",
            "position": "138"
          },
          "Protein Change": {
            "ref": "E",
            "alt": "K",
            "position": "46"
          },
          "Description in input context": "E46K mutation... increased the propensity to fibrillize"
        },
        {
          "HGVS": "NM_000305.1:c.159G>C",
          "cDNA Change": {
            "transcript": "NM_000305.1",
            "ref": "G",
            "alt": "C",
            "position": "159"
          },
          "Protein Change": {
            "ref": "A",
            "alt": "T",
            "position": "53"
          },
          "Description in input context": "A53T mutation... greater effect than E46K"
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Parkinson's disease",
    "MONDO": "MONDO:0006128"
  },
  "Experiment Method": [
    {
      "Assay Method": "In vitro fibrillation assay",
      "Material used": {
        "Material Source": "Protein",
        "Material Name": "α-synuclein",
        "Description": "Assessment of mutation effects on protein aggregation"
      },
      "Readout type": "Qualitative",
      "Readout description": [
        {
          "Variant": "NM_000305.1:c.138G>A",
          "Conclusion": "Abnormal",
          "Molecular Effect": "increased fibrillation propensity",
          "Result Description": "E46K mutation increased fibrillation rate compared to wild-type"
        },
        {
          "Variant": "NM_000305.1:c.159G>C",
          "Conclusion": "Abnormal",
          "Molecular Effect": "greater fibrillation effect",
          "Result Description": "A53T mutation showed more pronounced aggregation than E46K"
        }
      ],
      "Biological replicates": {
        "Biological replicates": "N.D.",
        "Description": "Not explicitly mentioned in the text"
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "Not explicitly mentioned in the text"
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Wild-type α-synuclein used as control"
      },
      "Basic negative control": {
        "Basic negative control": "N.D.",
        "Description": "Not explicitly mentioned in the text"
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "N.D."
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "N.D."
      },
      "Statistical analysis method": {
        "Statistical analysis method": "N.D."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Fibril formation detected by SDS-PAGE",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Fibril formation rate > 50% in 72 hours",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    }
  ]
}